Home-based Cervical Cancer Screening Project (CASAHO)

January 14, 2025 updated by: Prof. Patrick Petignat

Offering Home-based Versus Hospital-based HPV Counseling and Testing for Cervical Cancer Screening in Rural West Region of Cameroon: a Randomised Cluster Trial

Cervical cancer is a public health problem in Cameroon.In 2020, the country had a crude incidence of 20.2 per 100 000 women for an incidence to mortality ratio of 0.65. As for now, the country does not have a national screening program to combat the disease. Only 6% of cameroonian women have once been screened for cervical cancer. In order to increase screening uptake so as to reach 70% recommended by the World Health Organization (WHO), a home-based cervical cancer screening approach is proposed. The objective of our study is to compare two recruitment strategies for cervical cancer screening in rural Cameroon.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In 2018, a 5 years cervical cancer screening project called: "Promoting Comprehensive Cervical Cancer Prevention and Better Women's Health in Low- and Medium Resource Settings in the Health District of Dschang" was launched in the West Region of Cameroon. The study aimed at screening 2000 women per year following screen-triage-treatment as recommended by WHO in a 3T approach: Test with HPV self-sampling test, Triage by visual assessement of the cervix with acetic acid and lugol (VIA/VILI), Treatment with thermal ablation. Despite sensitization using communication information channels, uptake of the screening was below the target. In order to increase uptake of the screening, this study proposes a home-based strategy using Community Health Workers (CHW). Community Health Workers (CHW) are lay members of the community who carry out health promotion activities after training. In a randomised controlled cluster trial, two recruitment strategies for cervical cancer screening will be compared: in one arm a team made up of a CHW and a nurse will do door-to-door sensitization and propose home-based HPV self-sampling test to eligible women and in the other arm CHW will do door-to-door sensitization and issue invitation cards to eligible women for hospital-based HPV self-sampling test. This study is nested in ongoing cervical cancer screening project.

Primary objective: To compare completeness of full screening between two different recruitment strategies in rural area: counselling and home-based HPV self-sampling test versus counselling and hospital-based HPV self-sampling test.

Secondary objectives:

  • To determine the proportion of women who will carry out an HPV self-sampling test in both strategies within 3 months of sensitization.
  • To determine the proportion of HPV positive women who will undergo VIA/VILI in both arms within 3 months.
  • To assess the acceptability of home self-sampling HPV test and perception of single versus 2 visits approaches.
  • To determine predictors of non-adherence to care-seeking for HPV positive women.
  • To determine the number of pre-cancers and/or cancers diagnosed in both arms and their treatment.
  • To calculate the economic cost of both strategies.

Mixed method design, quantitative and qualitative informations will be collected.

Study Type

Interventional

Enrollment (Actual)

2079

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Cameroon
    • Menoua
      • Dschang, Menoua, Cameroon
        • Dschang District Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women aged 30-49 years
  • Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).

Non-inclusion criteria:

  • Pregnancy at the time of screening
  • History of cervical cancer screening by HPV test of less than 5 years (for HIV-negative women) or less than 3 years (for HIV positive women).
  • Intra-vaginal treatment

Exclusion Criteria:

  • Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass)
  • Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure)
  • Women who are not able to comply with the study protocol.
  • Previous hysterectomy
  • Known cervical cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: home-based
A team made up of a Community Health Worker (CHW) and a nurse will do door-to-door sensitization and propose to eligible women to undergo HPV self-sampling test at home. Samples collected will be taken by the nurse to the hospital for HPV testing . Participants will receive a phone call: disclosure of the HPV test's result will be by phone call for HPV-negative participants; HPV-positive participants will be invited to the hospital for disclosure of their results. At the hospital, HP-positive participants will undergo visual assessment of their cervix and treatment if needed.
Other: Experimental
Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.
Active Comparator: hospital-based
Community Health Worker (CHW) will do door-to-door sensitization and invite eligible women to attend cervical cancer screening at District Hospital Dschang. At the hospital they will do HPV self-sampling test. HPV-negative women will be advised to repeat the test after 5 years while HPV positive women will undergo visual assessment of the cervix with acetic acid and lugol (VIA/VILI) and treatment if needed.
Other: Active comparator
Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number and percentage of participants who will complete full screening (HPV test +/- VIA/VILI +/- treatment when necessary) in both arms within 3 months of sensitization
Time Frame: 3 months
The number and percentage of participants who will do an HPV self test+/- VIA/VILI+/- treatment par study arm
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number and percentage of women who will do an HPV test within 3 months of sensitization per study arm
Time Frame: 3 months from sensitization
The number and percentage of participants who will do an HPV test in each arm of the study.
3 months from sensitization
Number and percentage of participants once tested HPVpositive who will link to the pelvic exam for visual assessment and treatment (if needed) within 3 months.
Time Frame: 3 months from HPV self sample collection
The number and percentage of participants once tested HPV positive who link to the hospital for visual assessment of the cervix and treatment if needed.
3 months from HPV self sample collection
Identify barriers and enablers to the home-HPV self-sampling test.
Time Frame: 4 months
Factors that prevent and motivate women to participate to a home-based HPV self-test.
4 months
Identify barriers and enablers of linkage to VIA for HPV positive women
Time Frame: 4 months
Factors that prevent and motivate participants who did a home-based HPV self-test to link to the hospital for visual assesment of the cervix using acetic acid and lugol (VIA/VILI).
4 months
Number of pre-cancers and/or cancers diagnosed in each study arm.
Time Frame: 2 years
The number of pre-cancers and cancers diagnosed per study arm.
2 years
Cost of each screening strategy.
Time Frame: 2 years
The cost of each strategy and make a cost-effectiveness analysis.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Prof. Patrick Petignat

Collaborators

Dschang District Hospital

Investigators

  • Principal Investigator: Patrick Petignat, Pr, University Hospital, Geneva

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 27, 2023

Primary Completion (Actual)

August 31, 2024

Study Completion (Actual)

August 31, 2024

Study Registration Dates

First Submitted

December 4, 2023

First Submitted That Met QC Criteria

December 4, 2023

First Posted (Actual)

December 12, 2023

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 14, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • N°2022/10/1494/CE/CNERSH/SP

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Anonymised data may be shared upon reasonable request at the end of the study period.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe